Dolutegravir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dolutegravir |
| DrugBank ID | DB08930 |
| Brand Names (EU) | Tivicay |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.90% |
Approved Indication (EMA)
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.90% | DL |
| 2 | feline acquired immunodeficiency syndrome | 99.85% | DL |
| 3 | simian immunodeficiency virus infection | 99.85% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.80% | DL |
| 5 | AIDS | 98.14% | DL |
| 6 | chronic hepatitis C virus infection | 96.39% | DL |
| 7 | congenital human immunodeficiency virus | 96.39% | DL |
| 8 | AIDS related complex | 96.39% | DL |
| 9 | hepatitis C virus infection | 93.66% | DL |
| 10 | obsolete familial combined hyperlipidemia | 93.42% | DL |
| 11 | hepatitis E virus infection | 92.47% | DL |
| 12 | hepatitis A virus infection | 92.28% | DL |
| 13 | Omsk hemorrhagic fever | 92.18% | DL |
| 14 | hepatitis, viral, animal | 92.05% | DL |
| 15 | Kyasanur forest disease | 91.98% | DL |
| 16 | fibroma of prostate | 91.97% | DL |
| 17 | Brenner tumor | 91.78% | DL |
| 18 | benign reproductive system neoplasm | 91.69% | DL |
| 19 | benign prostate phyllodes tumor | 91.44% | DL |
| 20 | hepatitis B virus infection | 91.25% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.